Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
NUVOLA TRIAL Open-label Multicentre Study

peritoneal tumour load. Nonetheless, BRCAmut women additionally show a higher benefit of platinum-based neoadjuvant chemotherapy (NACT) plus interval debulking surgery compared with BRCAwt women in

  • 0 views
  • 23 Jan, 2021
  • 1 location
Prehabilitation in Patients With Advanced Stage Ovarian Cancer Planned for Interval Debulking Surgery

There is a strong evidence of positive effect of multimodal prehabilitation from prospective controlled trials among patients treated surgically for non-gynaecological cancer. However, the number of studies published on prehabilitation programs in gynaecologic surgery are limited, especially in gynaecologic cancer patients. No study or trial comprehensively evaluating a prehabilitation pathway …

  • 0 views
  • 16 Mar, 2021
  • 1 location
Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian Cancer

status. Neoadjuvant chemotherapy(NAC) followed interval debulking surgery (IDS) is an alternative therapeutic option for these patients. There is growing interest in the use of HIPEC (hyperthermic

cancer of the ovary
residual tumor
ovarian epithelial carcinoma
intraperitoneal chemotherapy
tumor debulking
  • 8 views
  • 23 Jan, 2021
  • 1 location
Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian Fallopian and Primary Peritoneal Cancer

Te hypothesized that two cycles of neoadjuvant chemotherapy followed by interval debulking surgery would improve survival in advanced epithelial ovarian, fallopian, and primary peritoneal cancer

cancer antigen 125
ascites
tumor debulking
l alanine
cancer
  • 45 views
  • 23 Jan, 2021
Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting

This study aims to evaluate the effects of niraparib in those who have received neoadjuvant chemotherapy and subsequent interval debulking surgery, with or without hyperthermic intraperitoneal

carboplatin
cancer of the ovary
parp inhibitor
niraparib
intraperitoneal chemotherapy
  • 0 views
  • 25 Jan, 2021
  • 1 location
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)

(PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This study aims to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC combined with standard care

targeted therapy
primary debulking surgery
cancer of the ovary
mucinous adenocarcinoma
cytoreduction
  • 3 views
  • 22 Jan, 2021
  • 12 locations
Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian Cancer

arm clinical trial. Included patients will receive interval debulking surgery after 2-6 cycles neoadjuvant chemotherapy based on the clinical judgment of the gynecologic oncologist. Six cycles of

  • 0 views
  • 18 Aug, 2021
  • 1 location
Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy

surgery. [18F]FB-IL2 PET-CT will be used for the non-invasive assessment of T-cell activation and correlated to immunohistochemistry tumor tissue data from pre-treatment biopsy and interval debulking

carboplatin
cancer of the ovary
ascites
tumor debulking
paclitaxel
  • 2 views
  • 23 May, 2021
  • 1 location
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)

The purpose of this study is to answer the fundamental question, should the physicians choose Surgery or Chemotherapy (SOC 2) in advanced ovarian cancer?

cancer antigen 125
cancer of the ovary
cytoreduction
cancer
serum bilirubin level
  • 505 views
  • 23 Jan, 2021
  • 7 locations
Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer

This study was designed to assess the safety and efficacy of neoadjuvant therapy with mitomycin C plus cisplatin (MP) in BRCA1-mutated ovarian cancer versus standard regimen (paclitaxel plus carboplatin (TP)).

  • 0 views
  • 18 Feb, 2021
  • 1 location